Cells were harvested, lysed, and subjected to SDS-PAGE 4 weeks after infection as described previously.
17 The following primary antibodies were used: phospho-Stat3 (Tyr
705), Stat3, Hif-1α
, MMP-2, MMP-9, phospho-PI3K p85 (Tyr
458), PI3K p85, phospho-Akt (Ser
473), Akt, phospho-ERK1/2 (Thr
202/Tyr
204), ERK1/2, E-cadherin, N-cadherin,
β-catenin, Vimentin, Snail, TCF8/Zeb1, PARP, phospho-Lyn (Tyr
507), Lyn, Fyn, phospho-Src (Tyr
416), Src, phospho-Syk (Tyr
323), phospho-Syk (Tyr
525/526), Syk, phospho-Smad2/3 (Ser
465/467/Ser
423/425), Smad2/3, ▵p63, CNX43, and β-actin from Cell Signaling Technology (1:1000; Beverly, MA); phospho-Fyn (Thr
12), EBNA-2, EBNA-3A, LMP-1, LMP-2A, Ang-1, and VEGF from Santa Cruz Biotechnology (1:200; Santa Cruz, CA); EBNA-1 from Thermo Scientific (1:50; Rockford, IL); and
β-tubulin from BD Biosciences (1:500; San Diego, CA).